Abstract
Forty patients with inoperable pancreatic cancer were included in a prospective, randomised, controlled trial of multiple chemotherapy. The survival of 19 untreated control patients was compared with that of 21 patients who received an initiation course of intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter. Median survival in treated patients was 44 weeks, which was significantly longer than the nine weeks seen in controls. In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls. In patients with metastases it was 30 weeks in treated patients and seven weeks in controls. The treatment was well tolerated and seemed to confer a significant prolongation of survival, comparing favourably with previous reports of chemotherapy with or without radiotherapy. If the results are confirmed this regimen may be useful in district general hospital practice.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bitran J. D., Desser R. K., Kozloff M. F., Billings A. A., Shapiro C. M. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2049–2051. [PubMed] [Google Scholar]
- Buroker T., Kim P. N., Groppe C., McCracken J., O'Bryan R., Panettiere F., Costanzi J., Bottomley R., King G. W., Bonnet J. 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study. Cancer. 1979 Oct;44(4):1215–1221. doi: 10.1002/1097-0142(197910)44:4<1215::aid-cncr2820440408>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Carter S. K., Comis R. L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev. 1975 Sep;2(3):193–214. doi: 10.1016/s0305-7372(75)80003-x. [DOI] [PubMed] [Google Scholar]
- Hanham I. W., Newton K. A., Westbury G. Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime. Br J Cancer. 1971 Sep;25(3):462–478. doi: 10.1038/bjc.1971.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KARNOFSKY D. A. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther. 1961 Nov-Dec;2:709–712. doi: 10.1002/cpt196126709. [DOI] [PubMed] [Google Scholar]
- Krauss S., Sonoda T., Solomon A. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer. 1979 May;43(5):1598–1603. doi: 10.1002/1097-0142(197905)43:5<1598::aid-cncr2820430505>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Douglas H. O., Jr, Hanley J., Carbone P. P. Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. Cancer. 1977 Aug;40(2):605–608. doi: 10.1002/1097-0142(197708)40:2<605::aid-cncr2820400202>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schein P. S., Lavin P. T., Moertel C. G., Frytak S., Hahn R. G., O'Connell M. J., Reitemeier R. J., Rubin J., Schutt A. J., Weiland L. H. Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer. 1978 Jul;42(1):19–22. doi: 10.1002/1097-0142(197807)42:1<19::aid-cncr2820420103>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- Wiggans R. G., Woolley P. V., Macdonald J. S., Smythe T., Ueno W., Schein P. S. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer. 1978 Feb;41(2):387–391. doi: 10.1002/1097-0142(197802)41:2<387::aid-cncr2820410201>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]